Notice for osimertinib (AstraZeneca Pty Ltd)
Active ingredients
osimertinib
Sponsor
Date of review outcome
Lapse date
Type
Priority Review
Dosage form(s)
Tablet
Indication
For the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Registration date